Seres reports early trial data for SER-155 in cancer therapy side effect

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. GOOG
6. AMD
7. CSX
8. INTC
9. IBM
10. KNX

Go back to Seres reports early trial data for SER-155 in cancer therapy side effect
(NASDAQ: MCRB) Delayed: 5.27 -0.01 (0.19%)
Previous Close $5.28    52 Week High $44.51 
Open $5.21    52 Week Low $8.05 
Day High $5.36    P/E N/A 
Day Low $5.11    EPS $0.00 
Volume 25,906